Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.

Zinzani PL, Corradini P, Gallamini A, Grossi A, Lazzarino M, Marchetti M, Martelli M, Rossi G, Vitolo U.

Leuk Lymphoma. 2012 May;53(5):789-95. doi: 10.3109/10428194.2011.629701. Review.

PMID:
21980956
2.

Alemtuzumab in T-cell malignancies.

Dearden CE, Matutes E, Catovsky D.

Med Oncol. 2002;19 Suppl:S27-32. Review.

PMID:
12180489
3.

The role of alemtuzumab in the management of T-cell malignancies.

Dearden C.

Semin Oncol. 2006 Apr;33(2 Suppl 5):S44-52. Review.

PMID:
16720203
4.

Receptor-directed therapy of T-cell leukemias and lymphomas.

Morris JC, Waldmann TA, Janik JE.

J Immunotoxicol. 2008 Apr;5(2):235-48. doi: 10.1080/15476910802129661. Review.

PMID:
18569395
5.

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.

Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M.

Br J Haematol. 2009 Apr;145(2):173-9. doi: 10.1111/j.1365-2141.2009.07606.x.

6.

Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).

Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL.

Clin Cancer Res. 2006 Dec 1;12(23):7174-9.

7.

Alemtuzumab.

Ravandi F, O'Brien S.

Expert Rev Anticancer Ther. 2005 Feb;5(1):39-51. Review.

PMID:
15757437
8.

Alemtuzumab in CLL and other lymphoid neoplasms.

Ravandi F, O'brien S.

Cancer Invest. 2006 Nov;24(7):718-25. Review.

PMID:
17118783
9.

Alemtuzumab therapy in B-cell lymphoproliferative disorders.

Moreton P, Hillmen P.

Semin Oncol. 2003 Aug;30(4):493-501. Review.

PMID:
12939718
10.

Effect of alemtuzumab on neoplastic B cells.

Golay J, Manganini M, Rambaldi A, Introna M.

Haematologica. 2004 Dec;89(12):1476-83.

11.

A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy.

Donjacour CE, Lammers GJ.

J Sleep Res. 2012 Aug;21(4):479-80. doi: 10.1111/j.1365-2869.2011.00985.x. No abstract available.

12.

Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.

Anderson AE, Lorenzi AR, Pratt A, Wooldridge T, Diboll J, Hilkens CM, Isaacs JD.

Rheumatology (Oxford). 2012 Aug;51(8):1397-406. doi: 10.1093/rheumatology/kes038.

PMID:
22447884
13.

In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.

De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F.

Nucl Med Biol. 2008 Jul;35(5):599-604. doi: 10.1016/j.nucmedbio.2008.03.001.

PMID:
18589304
14.
15.

[Innovative antibody-therapies for malignant lymphomas].

Müller AM, Rawluk J, Thierry V, Brink I, Engelhardt M.

Dtsch Med Wochenschr. 2005 Dec 2;130(48):2783-8. Review. German.

PMID:
16307409
16.

The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.

Giralt S.

Semin Oncol. 2006 Apr;33(2 Suppl 5):S36-43. Review.

PMID:
16720202
17.

Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.

Amengual JE, Raphael BG.

Leuk Lymphoma. 2010 Jul;51(7):1347-50. doi: 10.3109/10428194.2010.486091. No abstract available.

PMID:
20572801
18.

Alemtuzumab in the treatment of chronic lymphocytic lymphoma.

Boyd K, Dearden CE.

Expert Rev Anticancer Ther. 2008 Apr;8(4):525-33. doi: 10.1586/14737140.8.4.525. Review.

PMID:
18402519
19.

Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab.

Shukla N, Kobos R, Renaud T, Teruya-Feldstein J, Price A, McAllister-Lucas L, Steinherz P.

Cancer. 2012 Aug 1;118(15):3719-24. doi: 10.1002/cncr.26712.

20.

Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).

Gautschi O, Blumenthal N, Streit M, Solenthaler M, Hunziker T, Zenhäusern R.

Eur J Haematol. 2004 Jan;72(1):61-3.

PMID:
14962265
Items per page

Supplemental Content

Support Center